Rani Therapeutics Holdings, Inc. (RANI)Healthcare | Biotechnology | San Jose, United States | NasdaqGM
0.73 USD
-0.02
(-2.357%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:01 a.m. EDT
The investment case here is fundamentally broken. The company has suffered a catastrophic multi-year collapse, dropping nearly 98% from its peak, with the most recent annual performance showing an 80% decline. Despite a recent uptick in the trailing twelve-month figure, the business is hemorrhaging cash with negative operating margins and no revenue growth to speak of. The balance sheet, while currently liquid, cannot sustain this burn without further capital raises that will likely dilute shareholders. Analyst targets are mathematically impossible given the lack of earnings, and insider buying appears to be opportunistic rather than a vote of confidence in the turnaround. With no dividend to provide income and a trajectory that suggests the market has permanently downgraded the asset's quality, there is no rational basis for a long-term hold. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.180224 |
| AutoTheta | 0.443945 |
| AutoETS | 0.458850 |
| AutoARIMA | 0.464637 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.41 |
| Ljung-Box p | 0.105 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.396 |
| Revenue per Share | 0.035 |
| Market Cap | 103,028,912 |
| Forward P/E | -3.86 |
| Beta | 0.71 |
| Website | https://www.ranitherapeutics.com |
As of Oct. 10, 2026, 2:01 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $0.50 strike, while call interest is concentrated far out-of-the-money at $1.50 and $2.50 strikes. This distribution suggests a 'long gamma' strategy where traders are betting on volatility expansion rather than immediate directional moves, effectively hedging against further downside while waiting for a catalyst to push the price higher.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5326531 |
| Address1 | 2,051 Ringwood Avenue |
| All Time High | 36.27 |
| All Time Low | 0.387 |
| Ask | 1.0 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 466,240 |
| Average Daily Volume3 Month | 728,192 |
| Average Volume | 728,192 |
| Average Volume10Days | 466,240 |
| Beta | 0.712 |
| Bid | 0.76 |
| Bid Size | 9 |
| Book Value | 0.349 |
| City | San Jose |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7332 |
| Current Ratio | 5.313 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.7659 |
| Day Low | 0.71 |
| Debt To Equity | 7.396 |
| Display Name | Rani Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,774,557,000 |
| Earnings Call Timestamp Start | 1,774,557,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -32,237,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.351 |
| Enterprise To Revenue | 8.927 |
| Enterprise Value | 43,538,580 |
| Eps Current Year | -0.17333 |
| Eps Forward | -0.19 |
| Eps Trailing Twelve Months | -0.15 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.81762 |
| Fifty Day Average Change | -0.084419966 |
| Fifty Day Average Change Percent | -0.10325086 |
| Fifty Two Week Change Percent | 53.26531 |
| Fifty Two Week High | 3.87 |
| Fifty Two Week High Change | -3.1367998 |
| Fifty Two Week High Change Percent | -0.8105426 |
| Fifty Two Week Low | 0.462 |
| Fifty Two Week Low Change | 0.2712 |
| Fifty Two Week Low Change Percent | 0.58701295 |
| Fifty Two Week Range | 0.462 - 3.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 82,316,464 |
| Forward Eps | -0.19 |
| Forward P E | -3.8589475 |
| Free Cashflow | -8,874,375 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 69 |
| Fullday Change | 0.016799986 |
| Fullday Change Percent | 2.291324 |
| Fullday Price | 0.75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 4,877,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04908 |
| Held Percent Institutions | 0.46806 |
| Implied Shares Outstanding | 140,519,513 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. |
| Long Name | Rani Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 103,028,912 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_242425883 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -30,141,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 88,530,944 |
| Number Of Analyst Opinions | 5 |
| Open | 0.75 |
| Operating Cashflow | -20,292,000 |
| Operating Margins | -5.16862 |
| Phone | 408 457 3700 |
| Pre Market Change | 0.016799986 |
| Pre Market Change Percent | 2.291324 |
| Pre Market Price | 0.75 |
| Pre Market Time | 1,791,970,870 |
| Previous Close | 0.7509 |
| Price Eps Current Year | -4.2300816 |
| Price Hint | 4 |
| Price To Book | 2.1008596 |
| Price To Sales Trailing12 Months | 21.12547 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.23 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.0177 |
| Regular Market Change Percent | -2.35717 |
| Regular Market Day High | 0.7659 |
| Regular Market Day Low | 0.71 |
| Regular Market Day Range | 0.71 - 0.7659 |
| Regular Market Open | 0.75 |
| Regular Market Previous Close | 0.7509 |
| Regular Market Price | 0.7332 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 918,637 |
| Return On Assets | -0.52994996 |
| Return On Equity | -1.72147 |
| Revenue Per Share | 0.035 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 115,424,960 |
| Shares Percent Shares Out | 0.062800005 |
| Shares Short | 7,249,790 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,389,683 |
| Short Name | Rani Therapeutics Holdings, Inc |
| Short Percent Of Float | 0.0645 |
| Short Ratio | 13.12 |
| Source Interval | 15 |
| State | CA |
| Symbol | RANI |
| Target High Price | 11.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.2 |
| Target Median Price | 6.0 |
| Total Cash | 53,391,000 |
| Total Cash Per Share | 0.463 |
| Total Debt | 3,549,000 |
| Total Revenue | 4,877,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.98634 |
| Two Hundred Day Average Change | -0.25313997 |
| Two Hundred Day Average Change Percent | -0.25664577 |
| Type Disp | Equity |
| Volume | 918,637 |
| Website | https://www.ranitherapeutics.com |
| Zip | 95,131 |